Iron-Deficiency Anemia

Burz, Claudia; Cismaru, Cosmin Andrei; Pop, Vlad; Bojan, Anca

doi:10.5772/intechopen.80940

Cited by 12 publications

(19 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, though consuming your greens as part of an overall diet of anemia is helpful, do not rely solely on them to treat your disease. (Burz et al, 2019) vitamin C helps your stomach absorb iron.Leafy greens can increase iron absorption by eating food containing vitamin C, including oranges, red peppers & strawberries. Some greens, such as collard greens and Swiss chard, are healthy sources of both iron and vitamin C.…”

Section: Figure 4: Shows the Patients Reasons For Giving Upmentioning

confidence: 99%

Effects and Alternatives to Haematinics on Anemic Patients-A Questionnaire Study

Dharsan¹

2020

Biosci. Biotech. Res. Comm

View full text Add to dashboard Cite

Study of the alternatives and side effects of haematinics on anaemic patients. Anaemia is a condition which can be either hereditary or acquired with an abnormal RBC. Anemia are usually treated by Haematinics in the form of tablets, capsules and syrup and sometimes injection. Long term intake of haematinics produces some side effects like Gastritis, tooth staining, etc. This study was conducted to analyse the side effects experienced by anemia patients due to haematinics. This is a survey based study, A questionnaire was prepared regarding hematinics and alternate to haematinics. From the derived data the difficulty and side effects of haematinics were studied and analysed.Adverse effects of oral iron: epigastric pain, nausea, vomiting, gastritis, metallic taste, constipation (due to astringent effect) or diarrhea (irritant effect) are the usual adverse effects. Liquid preparations of iron causes staining of teeth. Many people preferred natural alternatives to haematinics. The survey says that some groups of people preferred natural products over hematinic drugs for their treatment of anaemia due to its side effects.

show abstract

Section: Figure 4: Shows the Patients Reasons For Giving Upmentioning

confidence: 99%

Effects and Alternatives to Haematinics on Anemic Patients-A Questionnaire Study

Dharsan¹

2020

Biosci. Biotech. Res. Comm

View full text Add to dashboard Cite

show abstract

“…In people older than 65 years its prevalence is 12%. World Health Organization (WHO) data show that ID/IDA in pregnancy is a significant problem throughout the world with a prevalence ranging Iron Metabolism -Iron a Double-Edged Sword from an average of 14% of pregnant women in industrialized countries to an average of 56% (range 35-75%) in developing countries [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…Vegetarians, especially vegans, obese individuals, blood donors and competitive endurance athletes represent populations at risk of ID/IDA. In children increased daily requirement and CD are the leading causes of ID/IDA [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…This process is regulated by the cytochrome B (DCYTB), a ferric reductase located on the apical membrane of duodenal enterocytes. Otherwise heme-iron is absorbed in the same bowel district, but separately from DMT1 and more efficiently than inorganic Fe [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…Subsequently iron replacement is always indicated to replete iron stores. The use of oral iron formulations is the current standard treatment; however in certain situations discussion remain open if the intravenous iron might be a more suitable modality for iron supplementation [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

FERALGINE™ a New Oral iron Compound

Talarico¹,

Giancotti²,

Mazza³

et al. 2022

Iron Metabolism - A Double-Edged Sword

View full text Add to dashboard Cite

Management of iron deficiency (ID) and iron deficiency anemia (IDA) is primarily focused to remove, when possible, the underlying cause of ID; subsequently its treatment is primary focused on iron stores repletion. Ferrous sulphate (FS) remains the mainstay of treatment and it is recommended as the first-line treatment of ID and IDA in children as in adults by all guidelines of scientific societies. However the effectiveness of FS is largely compromised by increased adverse effects, poor compliance and discontinuation of treatment. A new oral iron source named FERALGINE™ (FBC-A) has been recently developed. This new molecule is a patented co-processed one-to-one ratio compound between Ferrous Bysglicinate Chelate (FBC) and Sodium Alginate (AA), obtained by using a spray drying technology. The data presented in this short review highlight the efficacy and safety of the treatment with FBC-A and support its use in adult patients with IDA. Furthermore the present review also provides preliminary evidence to suggest FBC-A as first-line treatment for ID/IDA in patients with celiac disease (CD) or inflammatory bowel diseases (IBD).

show abstract

Nutritional deficiency anemia and post‐acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: A six‐month retrospective cohort analysis of 30 892 patients

Wu,

Liu,

Hung

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The effect of anemia on the post‐acute outcome of patients with severe acute respiratory syndrome coronavirus 2 infection was unclear. This study aimed to investigate the potential association between nutritional deficiency anemia (NDA) status and post‐acute sequelae of patients with SARS‐CoV‐2 infection. This retrospective cohort study included patients with coronavirus disease (COVID‐19) from January 1, 2022 to November 30, 2022 using the TriNetX research network. The patients were grouped into the NDA group comprising patients diagnosed with NDA and the control group comprising patients without NDA, and propensity score matching (PSM) was performed to balance the two groups. The primary outcome was a composite of post‐COVID‐19 condition, all‐cause hospitalization, and all‐cause death. The secondary outcomes were any individual outcomes of the primary composite. The follow‐up period was set at 90–180 days after COVID‐19 diagnosis. Two cohorts comprising 15 446 nonhospitalized patients with COVID‐19 in each group with balanced baseline characteristics were created using PSM. During the follow‐up period, the NDA group demonstrated a higher risk of the composite primary outcome, including post‐COVID‐19 condition, all‐cause hospitalization, or all‐cause death (hazard ratio [HR], 1.896; 95% confidence interval [CI] = 1.757–2.045). Regarding secondary outcomes, the NDA group was associated with worse outcomes, including post‐COVID‐19 condition (HR, 1.992; 95% CI = 1.403–2.828), all‐cause hospitalization (HR, 1.856; 95% CI = 1.714–2.009), and all‐cause death (HR, 3.922; 95% CI = 2.910–5.285) compared to the control group. Among nonhospitalized patients with COVID‐19, NDA was associated with a higher risk of post‐COVID‐19 condition, all‐cause hospitalization, and all‐cause death during the 90–180‐day follow‐up period.

show abstract

Iron-Deficiency Anemia

Cited by 12 publications

References 68 publications

Effects and Alternatives to Haematinics on Anemic Patients-A Questionnaire Study

Effects and Alternatives to Haematinics on Anemic Patients-A Questionnaire Study

FERALGINE™ a New Oral iron Compound

Nutritional deficiency anemia and post‐acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: A six‐month retrospective cohort analysis of 30 892 patients

Contact Info

Product

Resources

About